LAG3 is not expressed in human and murine neurons and does not modulate α-synucleinopathies
Abstract
While the initial pathology of Parkinson’s disease and other α-synucleinopathies is often confined to circumscribed brain regions, it can spread and progressively affect adjacent and distant brain locales. This process may be controlled by cellular receptors of α-synuclein fibrils, one of which was proposed to be the LAG3 immune checkpoint molecule. Here, we analyzed the expression pattern of LAG3 in human and mouse brains. Using a variety of methods and model systems, we found no evidence for LAG3 expression by neurons. While we confirmed that LAG3 interacts with α-synuclein fibrils, the specificity of this interaction appears limited. Moreover, overexpression of LAG3 in cultured human neural cells did not cause any worsening of α-synuclein pathology ex vivo. The overall survival of A53T α-synuclein transgenic mice was unaffected by LAG3 depletion and the seeded induction of α-synuclein lesions in hippocampal slice cultures was unaffected by LAG3 knockout. These data suggest that the proposed role of LAG3 in the spreading of α-synucleinopathies is not universally valid.
Competing Interest Statement
AA is a member of the board of directors of Mabylon AG which has funded antibody-related work in the Aguzzi lab in the past. All other authors declare no competing interests.
Subject Area
- Biochemistry (13210)
- Bioengineering (10052)
- Bioinformatics (32212)
- Biophysics (16592)
- Cancer Biology (13671)
- Cell Biology (19422)
- Clinical Trials (138)
- Developmental Biology (10497)
- Ecology (15572)
- Epidemiology (2067)
- Evolutionary Biology (19877)
- Genetics (13139)
- Genomics (18199)
- Immunology (13305)
- Microbiology (31169)
- Molecular Biology (12966)
- Neuroscience (67972)
- Paleontology (498)
- Pathology (2093)
- Pharmacology and Toxicology (3634)
- Physiology (5665)
- Plant Biology (11658)
- Synthetic Biology (3263)
- Systems Biology (7960)
- Zoology (1798)